Ingredient or product comparison
AHK-Cu vs GHK-Cu: Research Application Comparison
In vitro collagen synthesis assay (72-hour endpoint, serum-free media) 340% increase over baseline at 10 μM; maximal effect by 48 hours 230% increase at 10 μM; continued rise through 72 hours AHK-Cu AHK-Cu delivers faster, higher-magnitude collagen deposition
This source-based comparison does not add ratings or recommend a winner.
- In vitro collagen synthesis assay (72-hour endpoint, serum-free media)
- 340% increase over baseline at 10 μM; maximal effect by 48 hours
- 230% increase at 10 μM; continued rise through 72 hours
- AHK-Cu
- AHK-Cu delivers faster, higher-magnitude collagen deposition in controlled serum-free conditions where its stable copper binding remains intact throughout the assay period
- Acute wound healing model (7–14 days, topical application)
- 42% faster wound closure; moderate tensile strength improvement
- 68% faster closure; 2.3× tensile strength vs control
- GHK-Cu
- GHK-Cu's anti-inflammatory activity and MMP inhibition produce superior functional healing outcomes despite lower absolute collagen synthesis rates
- UV-damaged skin model (photoaging prevention, 28-day protocol)
- Minimal reduction in MMP-1 expression; no TIMP modulation
- 47% MMP-1 reduction; 62% TIMP-1 increase; preserved dermal thickness
- GHK-Cu addresses both collagen degradation and synthesis pathways, essential for long-term photoprotection where ongoing UV exposure sustains inflammatory damage
- Scar tissue remodeling research (hypertrophic scar, 60-day treatment)
- Increased collagen density without improving alignment; risk of over-proliferation
- Balanced collagen deposition with improved fiber organization and reduced TGF-β1 signaling
- GHK-Cu's broader pathway modulation prevents excessive fibrosis while promoting organized tissue remodeling. AHK-Cu's isolated TGF-β activation can worsen scar hypertrophy
- Neuroregeneration model (peripheral nerve injury, systemic dosing)
- No detectable activity outside injection site at 1 mg/kg
- Elevated BDNF, NGF, and GDNF in target tissue; improved axon regeneration markers
- GHK-Cu crosses biological barriers and delivers systemic neuroregenerative signaling that AHK-Cu's molecular properties cannot replicate
- Cost-sensitive large-scale study (budget constraint prioritization)
- 30–40% lower cost per milligram; stable at room temperature for 6 months
- Higher material cost; requires −20°C storage; shorter shelf life post-reconstitution
- When budget limits research scope and the endpoint measures collagen synthesis exclusively, AHK-Cu's cost efficiency and stability advantages justify its use